China Injectable Drug Delivery Devices Market, By Product Type (Formulations, Devices), Usage Pattern (Curative Care, Immunization, Other Usage Pattern), Mode of Administration (Skin, Circulatory/Muskoskeletal, Organs, Central Nervous System), Application (Hormonal Disorders, Oncology, Autoimmune Disorders, Orphan Diseases, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
China Injectable Drug Delivery Devices Market Analysis and Size
The growing incidence of chronic diseases has led to the wide use of drug delivery devices in common, mainly disposable syringes. The market has observed increased strategic developments in enhancing their production facility for manufacturing of various injectable drug delivery devices combined with different acquisitions and partnerships. Numerous pharmaceutical companies are involved in developing the injectable insulin using various pen injectors and auto injectors for convenience of patient with self injection.
Data Bridge Market Research analyses a growth rate in the injectable drug delivery devices market in the forecast period 2023-2030. The expected CAGR of injectable drug delivery devices market is tend to be around 18% in the mentioned forecast period. The market is valued at USD 52,164.9 million in 2022, and it would grow upto USD 196080.51 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
China Injectable Drug Delivery Devices Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Formulations, Devices), Usage Pattern (Curative Care, Immunization, Other Usage Pattern), Mode of Administration (Skin, Circulatory/ Muskoskeletal, Organs, Central Nervous System), Application (Hormonal Disorders, Oncology, Autoimmune Disorders, Orphan Diseases, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Market Players Covered
|
Baxter (U.S.), BD (U.S.), China Meheco Group Co., Ltd (China), Elcam Medical (U.S.), Lilly (U.S.), Mylan N.V. (U.S.), Novo Nordisk A/S (Denmark), Pfizer Inc (U.S.), Agouron Pharmaceuticals (U.S.), AHP Holdings B.V. (Netherlands), Alacer Corp. (U.S.), Alpharma Pharmaceuticals LLC (U.S.), Bioren, LLC (U.S.), G.D. Searle & Co. Limited (U.K.)
|
|
Market Opportunities
|
|
Market Definition
The injectable method is the most commonly used method for drugs with poor oral bioavailability, targeted drug delivery systems, and delivery of drugs at the site of action. Injectable drug delivery is widely used in conditions such as cystic fibrosis, hemophilia, autoimmune diseases, pain, hormonal imbalance, Wilson’s disease, hepatitis C, and ribose-5-phosphate isomerase deficiency. Injectable drug delivery devices are the second most operating technology after oral drugs administration.
China Injectable Drug Delivery Devices Market Dynamics
Drivers
- Increasing Collaborations and Associations related to Auto-injectors
The auto-injectors is anticipated to witness huge growth due to the factors such as collaborations and partnerships of companies for auto-injectors, convenient usage, and the rising burden of chronic diseases. For instance, ALK Abello and China Grand Pharma entered into an exclusive licensing agreement in July 2021 for adrenaline auto-injector ALK’s AAI Jext to launch the product in China. Thus, this factor increases the market growth.
- Increasing Prevalence of Diabetes
The increasing occurrence of chronic diseases has led to the wide use of drug delivery devices in common, mainly disposable syringes. For instance, as per the International Diabetes Federation, Diabetes Atlas 2021, the age adjusted comparative prevalence of the diabetes in china for 2021 is projected as 10.6% and for 2030 as 11.8% and for 2045 as 12.5%. There is consistent raise in the incidence of diabetes in China which is projected to have led to the demand for prefilled syringes and autoinjectors in the forecast period.
Opportunities
- Increasing Demand For Rising Cancer Cases
As per the records of Cancer Research UK 2018, the population suffering from cancer is anticipated to surge in the future. According to the report, if the latest trends in prevalence of major cancers and population growth are consistent, it is anticipated there will be 27.5 million new cancer cases worldwide each year by 2040, than 17 million in 2018. As per the GLOBOCAN 2020 report, there are around 815,563 new cases of lung cancer, 555,477 cases of colorectal cancer, 478,508 cases of stomach cancer, 416,371 cases of breast cancer, and 410,038 cases of liver cancer. In 2022 it is anticipated that there will be around 4,820,000 new cancer cases in China, wherein the common type is lung cancer. Thus the higher occurrence of cancers has demand for drug delivery devices which are used in the treatment of cancers. Thus, this factor increases the market growth.
Restraints/Challenges
- Increased Expenditure of Treatment
The increased expenditure associated with the injectable drug delivery hinder the market growth. The increased cost associated with the manufacturing, supply and injectable drug delivery devices is often not possible for the developing and underdeveloped countries, cause the under treatment of numerous patients. This impedes the market growth.
This injectable drug delivery devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the injectable drug delivery devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on China Injectable Drug Delivery Devices Market
When the onset of COVID-19 pandemic, most of the pharmaceutical companies and governments worked to treat COVID-19 patients succesfully and drug delivery devices were anticipated to play an essential role in that context. For instance, CanSinoBIO received approval for the recombinant COVID-19 vaccine for Inhalation delivery in China in September 2022. Convidecia Air offers a non-invasive option by using a nebulizer to change liquid into an aerosol for inhalation through the mouth. Therefore, the huge advancements in the delivery of vaccines for COVID-19 surge the demand for drug delivery devices which aids the market to grow in the forecast period.
Recent Development
- In 2022, EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics received approval from China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg for the treatment of chronic non-infectious uveitis
- In 2020, Sanofi and Regeneron Pharmaceuticals received approval from China's National Medical Products Administration (NMPA) for Dupixent (dupilumab) for treating adults suffering from moderate to severe atopic dermatitis. Dupixent is widely available as a 300mg dose pre-filled syringe in China.
China Injectable Drug Delivery Devices Market Scope
The injectable drug delivery devices market is segmented on the basis of product type, application, usage pattern, mode of administration, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Formulations
- Devices
Usage Pattern
- Curative Care
- Immunization
- Other Usage Pattern
Mode of Administration
- Skin
- Circulatory/Muskoskeletal
- Organs
- Central Nervous System
Application
- Hormonal Disorders
- Oncology
- Autoimmune Disorders
- Orphan Diseases
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Competitive Landscape and China Injectable Drug Delivery Devices Market Share Analysis
The injectable drug delivery devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, China presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to injectable drug delivery devices market
Key players operating in the injectable drug delivery devices market include:
- Baxter (U.S.)
- BD (U.S.)
- China Meheco Group Co., Ltd (China)
- Elcam Medical (U.S.)
- Lilly (U.S.)
- Mylan N.V. (U.S.)
- Novo Nordisk A/S (Denmark)
- Pfizer Inc (U.S.)
- Agouron Pharmaceuticals (U.S.)
- AHP Holdings B.V. (Netherlands)
- Alacer Corp. (U.S.)
- Alpharma Pharmaceuticals LLC (U.S.)
- Bioren, LLC (U.S.)
- G.D. Searle & Co. Limited (U.K.)
SKU-